BR9910419A - Etm-305, etm-204, etm-775, substancialmente puros, processos para tratar leucemia de mamìferos, para tratar carcinoma de pulmão de mamìferos, para tratar adenocarcinoma de cólon de mamìferos, e para tratar melanoma maligno de mamìferos, composição farmacêutica, e, processo para testar o metabolismo citocromo humano cyp3a4 de ecteinascidina 743 - Google Patents

Etm-305, etm-204, etm-775, substancialmente puros, processos para tratar leucemia de mamìferos, para tratar carcinoma de pulmão de mamìferos, para tratar adenocarcinoma de cólon de mamìferos, e para tratar melanoma maligno de mamìferos, composição farmacêutica, e, processo para testar o metabolismo citocromo humano cyp3a4 de ecteinascidina 743

Info

Publication number
BR9910419A
BR9910419A BR9910419-9A BR9910419A BR9910419A BR 9910419 A BR9910419 A BR 9910419A BR 9910419 A BR9910419 A BR 9910419A BR 9910419 A BR9910419 A BR 9910419A
Authority
BR
Brazil
Prior art keywords
etm
treating mammalian
multiplayer
ecteinascidin
processes
Prior art date
Application number
BR9910419-9A
Other languages
English (en)
Inventor
Kenneth Lloyd
Jose J Morales
Joel Reid
Isabel Cuesta Reymundo
Pablo Floriano
Lola Gravalos Garcia
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of BR9910419A publication Critical patent/BR9910419A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/10—Quaternary compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"ETM-305, ETM-204, ETM-775, SUBSTANCIALMENTE PUROS, PROCESSOS PARA TRATAR LEUCEMIA DE MAMìFEROS, PARA TRATAR CARCINOMA DE PULMãO DE MAMìFEROS, PARA TRATAR ADENOCARCINOMA DE CóLON DE MAMìFEROS, E PARA TRATAR MELANOMA MALIGNO DE MAMìFEROS, COMPOSIçãO FARMACêUTICA, E, PROCESSO PARA TESTAR O METABOLISMO CITOCROMO HUMANO CYP3A4 DE ECTEINASCIDINA 743" A purificação e elucidação da estrutura de vários produtos do metabolismo de Et 743 por Citocromo humano CYP3A4 foram obtidos. Estes compostos são abreviados aqui como "ETM" seguido por um valor numérico que representa o peso molecular aproximado. Três compostos foram identificados até agora, ou seja ETM 305, ETM 775 e ETM 204. As estruturas destes metabólitos de ecteinascidina são mostradas como ETM 305, ETM 204 e ETM 775.
BR9910419-9A 1998-05-11 1999-05-11 Etm-305, etm-204, etm-775, substancialmente puros, processos para tratar leucemia de mamìferos, para tratar carcinoma de pulmão de mamìferos, para tratar adenocarcinoma de cólon de mamìferos, e para tratar melanoma maligno de mamìferos, composição farmacêutica, e, processo para testar o metabolismo citocromo humano cyp3a4 de ecteinascidina 743 BR9910419A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8502498P 1998-05-11 1998-05-11
PCT/US1999/010233 WO1999058125A1 (en) 1998-05-11 1999-05-11 Metabolites of ecteinascidin 743

Publications (1)

Publication Number Publication Date
BR9910419A true BR9910419A (pt) 2001-01-09

Family

ID=22188976

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910419-9A BR9910419A (pt) 1998-05-11 1999-05-11 Etm-305, etm-204, etm-775, substancialmente puros, processos para tratar leucemia de mamìferos, para tratar carcinoma de pulmão de mamìferos, para tratar adenocarcinoma de cólon de mamìferos, e para tratar melanoma maligno de mamìferos, composição farmacêutica, e, processo para testar o metabolismo citocromo humano cyp3a4 de ecteinascidina 743

Country Status (22)

Country Link
US (3) US6316214B1 (pt)
EP (1) EP1077698B1 (pt)
JP (2) JP4583598B2 (pt)
KR (1) KR100643092B1 (pt)
CN (3) CN100339375C (pt)
AT (1) ATE289810T1 (pt)
AU (1) AU759281B2 (pt)
BG (1) BG65235B1 (pt)
BR (1) BR9910419A (pt)
CA (1) CA2331593C (pt)
CZ (1) CZ302168B6 (pt)
DE (1) DE69923965T2 (pt)
ES (1) ES2239442T3 (pt)
HU (1) HUP0101960A3 (pt)
IL (2) IL139607A0 (pt)
NO (1) NO318081B1 (pt)
NZ (1) NZ508585A (pt)
PL (1) PL192409B1 (pt)
RU (1) RU2225864C2 (pt)
SK (1) SK285069B6 (pt)
TR (1) TR200003470T2 (pt)
WO (1) WO1999058125A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316214B1 (en) * 1998-05-11 2001-11-13 The Board Of Trustees Of The University Of Illinois ETM-775 metabolite of ecteinascidin 743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
PT1280809E (pt) * 2000-04-12 2005-11-30 Pharma Mar Sa Derivados antitumorais de ecteinascidina
US7919493B2 (en) * 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
CA2447553A1 (en) 2000-11-03 2002-05-23 President And Fellows Of Harvard College Saframycins, analogues and uses thereof
NZ525730A (en) * 2000-11-06 2004-12-24 Pharma Mar S Compositions for antitumour treatments containing Ecteinascidin 743
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US7407327B2 (en) * 2003-03-21 2008-08-05 Seagate Technology Llc Method and system for withstanding shock in a spindle motor bearing
PT1689404E (pt) 2003-11-13 2008-12-15 Pharma Mar Sau Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
PL1658848T3 (pl) 2004-10-29 2007-12-31 Pharma Mar Sa Preparaty zawierające ekteinascydynę i disacharyd
US20090325971A1 (en) * 2005-03-02 2009-12-31 The Trustees Of Columbia University In The City Of New York Pentacyclic Alkaloid Compounds and Methods of Use Thereof
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
US20090012157A1 (en) 2006-02-06 2009-01-08 Sears Barry D Sesamol Derivatives as Novel Inhibitors of Arachidonic Acid Formation
EP2786755A3 (en) 2010-11-12 2014-10-29 Pharma Mar S.A. Combination therapy with an antitumor alkaloid
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4273773A (en) 1979-09-24 1981-06-16 American Home Products Corporation Antihypertensive tricyclic isoindole derivatives
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
ATE69234T1 (de) 1986-06-09 1991-11-15 Univ Illinois Ekteinascidine 729, 743, 745, 759a, 759b and 770.
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
ATE158293T1 (de) 1992-06-19 1997-10-15 Hoechst Ag Polycyclische 31668p- und 31668u-verbindungen, verfahren zu ihrer herstellung und ihre verwendung als antibiotische oder antitumorale arzneistoffe
US5426108A (en) 1993-11-10 1995-06-20 American Cyanamid Company Antibiotic 31F508 ALPHA1, ALPHA2, BETA1 and BETA2
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5809563A (en) * 1996-11-12 1998-09-15 Institute For The Development Of Emerging Architectures, Llc Method and apparatus utilizing a region based page table walk bit
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
CA2327468C (en) * 1998-04-06 2008-05-06 The Board Of Trustees Of The University Of Illinois Semi-synthetic ecteinascidins
US6316214B1 (en) * 1998-05-11 2001-11-13 The Board Of Trustees Of The University Of Illinois ETM-775 metabolite of ecteinascidin 743
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
WO2001053299A1 (en) 2000-01-19 2001-07-26 The Trustees Of Columbia University In The City Of New York Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
PT1280809E (pt) 2000-04-12 2005-11-30 Pharma Mar Sa Derivados antitumorais de ecteinascidina
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.

Also Published As

Publication number Publication date
EP1077698B1 (en) 2005-03-02
US20050261326A1 (en) 2005-11-24
AU4073799A (en) 1999-11-29
SK285069B6 (sk) 2006-05-04
CN1195514C (zh) 2005-04-06
US6316214B1 (en) 2001-11-13
US6867334B2 (en) 2005-03-15
US20020032326A1 (en) 2002-03-14
US7115743B2 (en) 2006-10-03
AU759281B2 (en) 2003-04-10
JP2010215656A (ja) 2010-09-30
ES2239442T3 (es) 2005-09-16
WO1999058125A1 (en) 1999-11-18
NO20005671D0 (no) 2000-11-10
DE69923965T2 (de) 2006-04-06
CN100548988C (zh) 2009-10-14
ATE289810T1 (de) 2005-03-15
NZ508585A (en) 2002-11-26
TR200003470T2 (tr) 2001-06-21
NO20005671L (no) 2001-01-10
CZ20004183A3 (en) 2001-06-13
RU2225864C2 (ru) 2004-03-20
EP1077698A4 (en) 2002-05-08
EP1077698A1 (en) 2001-02-28
DE69923965D1 (de) 2005-04-07
KR20010071237A (ko) 2001-07-28
HUP0101960A2 (hu) 2001-11-28
NO318081B1 (no) 2005-01-31
CZ302168B6 (cs) 2010-11-24
JP4583598B2 (ja) 2010-11-17
PL192409B1 (pl) 2006-10-31
BG65235B1 (bg) 2007-09-28
KR100643092B1 (ko) 2006-11-10
CA2331593C (en) 2008-08-05
HUP0101960A3 (en) 2003-03-28
PL344183A1 (en) 2001-10-08
CA2331593A1 (en) 1999-11-18
CN1371279A (zh) 2002-09-25
IL139607A (en) 2006-12-10
CN1896064A (zh) 2007-01-17
IL139607A0 (en) 2002-02-10
BG105023A (en) 2001-08-31
SK17152000A3 (sk) 2001-07-10
JP2002514597A (ja) 2002-05-21
CN100339375C (zh) 2007-09-26
CN1683299A (zh) 2005-10-19

Similar Documents

Publication Publication Date Title
BR9910419A (pt) Etm-305, etm-204, etm-775, substancialmente puros, processos para tratar leucemia de mamìferos, para tratar carcinoma de pulmão de mamìferos, para tratar adenocarcinoma de cólon de mamìferos, e para tratar melanoma maligno de mamìferos, composição farmacêutica, e, processo para testar o metabolismo citocromo humano cyp3a4 de ecteinascidina 743
FR2430938A1 (fr) Nouvelles oxybenzylidenes bornanones, leur procede de preparation, et compositions cosmetiques les contenant
FI842419A0 (fi) 2-pyrimidinyl-1-piperazin-derivat, foerfarande foer deras framstaellning och dessa innehaollande laekemedel.
DE3364779D1 (en) Substituted 4-aminomethylene chromans or chromenes, process for their preparation and their use in medicines
PT75848A (en) 3-(1-substituted-4-piperidyl)-1,2-benzisoxazoles a processfor the preparation thereof a pharmaceutical composition comprising the same and their use as medicaments
ATE251624T1 (de) Granulatimide-derivate zur behandlung von krebs
JPS5665869A (en) Novel 22hydroxyalkyll3*4*55trihydroxyypiperidine compound* its manufacture and drug
DE60026725D1 (de) Verfahren zur herstellung von optisch aktiven naphthalinderivaten und darin eingesetzte optische resolver
ATE4117T1 (de) Pseudotrisaccharide, ihre herstellung und verwendung als arzneimittel.
DE69808922D1 (de) Thiazolobenzoheterocyclen, ihre herstellung und diese enthaltende phatrmazeutische zubereitungen
BR0013306A (pt) Processos úteis na sìntese de compostos antipicornavirais
ATE30159T1 (de) Anthracyclinderivate, verfahren zu ihrer herstellung ausgehend von einem stamm von mikroorganismen, der neue stamm streptomyces cyaneus und die verwendung der anthracyclinderivate als pharmazeutische praeparate.
ATE290869T1 (de) Verwendung von vitamin d derivaten zur herstellung eines medikaments zur behandlung von bösartigen tumormetastase
DE69815854D1 (de) Polyhydroxybutylpyrazinen, deren herstellung und diese enthaltende arzneimitteln
SE8103403L (sv) Germaniumforeningar, sett att framstella dem, sett att framstella ett lekemedelspreparat under anvendning av en dylik germaniumforening for behandling av cancer samt det pa sa sett erhallna lekemedelspreparatet
GEP19991535B (en) Process for the Preparation of 7-Hydroxy Taxanes
JPS57185270A (en) Novel cyclic sulfenamides, manufacture and use as drug
DE3164780D1 (en) 1-carba-6-(1-hydroxyethyl)-2-carbonyl-penem-3-carboxylic acid, process for preparing and pharmaceutical compositions comprising the same
DE60104866D1 (de) Aminoalkenylbenzoyl-benzofurane oder benzothiophene, verfahren zur ihrer herstellung und sie enthaltende zubereitungen
ATE265418T1 (de) Neue substituierte 3-phenoxy- und 3- phenylalkyloxy-2-phenyl-propylamine
DE3260248D1 (en) Compounds with antibiotic activity, process for their preparation and their use as medicaments
JPS574985A (en) Novel imidazolyl-indeno-thiophene compound, manufacture and pharmaceutical use
JPS5536485A (en) Nnaminoo3*4*55trihydoxypiperidines*their manufacture and use as drug
ATE155479T1 (de) Neue cytarabin-derivate, ihre herstellung und verwendung

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: REFERENTE A RPI NO 2164 DE 26/06/2012, POR TER SIDO INDEVIDA, VISTO O PEDIDO ESTAR ARQUIVADO.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 13A ANUIDADE.